Sutro Biopharma to Participate in Upcoming Investor Conferences
Sutro Biopharma (NASDAQ: STRO), a company specializing in antibody drug conjugates (ADCs) for oncology, has announced its participation in two upcoming investor conferences. The company will present at The Citizens Life Sciences Conference in New York from May 7-8, 2025, and the BofA Securities 2025 Health Care Conference in Las Vegas from May 13-15, 2025. Webcasts of both presentations will be available on Sutro's website investor relations section, with replays accessible for at least 30 days after each event.
Sutro Biopharma (NASDAQ: STRO), un'azienda specializzata in coniugati anticorpo-farmaco (ADC) per l'oncologia, ha annunciato la sua partecipazione a due prossimi convegni per investitori. La società presenterà a The Citizens Life Sciences Conference a New York dal 7 all'8 maggio 2025 e al BofA Securities 2025 Health Care Conference a Las Vegas dal 13 al 15 maggio 2025. Le trasmissioni in diretta di entrambe le presentazioni saranno disponibili nella sezione relazioni con gli investitori del sito web di Sutro, con la possibilità di rivederle per almeno 30 giorni dopo ogni evento.
Sutro Biopharma (NASDAQ: STRO), una empresa especializada en conjugados anticuerpo-fármaco (ADC) para oncología, ha anunciado su participación en dos próximas conferencias para inversores. La compañía presentará en The Citizens Life Sciences Conference en Nueva York del 7 al 8 de mayo de 2025, y en la BofA Securities 2025 Health Care Conference en Las Vegas del 13 al 15 de mayo de 2025. Las retransmisiones en directo de ambas presentaciones estarán disponibles en la sección de relaciones con inversores del sitio web de Sutro, con repeticiones accesibles durante al menos 30 días después de cada evento.
Sutro Biopharma (NASDAQ: STRO)는 종양학용 항체-약물 접합체(ADC)를 전문으로 하는 회사로, 다가오는 두 투자자 컨퍼런스에 참여할 예정입니다. 회사는 2025년 5월 7일부터 8일까지 뉴욕에서 열리는 The Citizens Life Sciences Conference와 2025년 5월 13일부터 15일까지 라스베이거스에서 개최되는 BofA Securities 2025 Health Care Conference에서 발표할 예정입니다. 두 발표 모두 Sutro 웹사이트의 투자자 관계 섹션에서 웹캐스트로 제공되며, 각 행사 후 최소 30일 동안 다시보기 서비스를 이용할 수 있습니다.
Sutro Biopharma (NASDAQ : STRO), une entreprise spécialisée dans les conjugués anticorps-médicaments (ADC) pour l'oncologie, a annoncé sa participation à deux prochaines conférences pour investisseurs. La société présentera lors de The Citizens Life Sciences Conference à New York du 7 au 8 mai 2025, ainsi qu'à la BofA Securities 2025 Health Care Conference à Las Vegas du 13 au 15 mai 2025. Les webdiffusions des deux présentations seront disponibles dans la section relations investisseurs du site web de Sutro, avec des rediffusions accessibles pendant au moins 30 jours après chaque événement.
Sutro Biopharma (NASDAQ: STRO), ein Unternehmen, das sich auf Antikörper-Wirkstoff-Konjugate (ADCs) für die Onkologie spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Das Unternehmen wird auf der The Citizens Life Sciences Conference in New York vom 7. bis 8. Mai 2025 sowie auf der BofA Securities 2025 Health Care Conference in Las Vegas vom 13. bis 15. Mai 2025 präsentieren. Webcasts beider Präsentationen werden im Investor-Relations-Bereich der Sutro-Website verfügbar sein, wobei Wiedergaben mindestens 30 Tage nach jeder Veranstaltung zugänglich sind.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in two upcoming investor conferences.
Conference Details:
The Citizens Life Sciences Conference
Date: May 7-8, 2025
Location: New York, NY
BofA Securities 2025 Health Care Conference
Date: May 13-15, 2025
Location: Las Vegas, NV
Webcasts of the presentations will be accessible through the News & Events page of the Investor Relations section of the Company’s website at www.sutrobio.com. Archived replays will be available for at least 30 days after the event.
About Sutro Biopharma
Sutro Biopharma, Inc., is relentlessly focused on the discovery and development of precisely designed cancer therapeutics to transform what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro is advancing a robust early-stage pipeline of novel exatecan and dual-payload antibody drug conjugates (ADCs), coupled with high-value collaborations and industry partnerships, which validate its continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.
Investor Contact
Emily White
Sutro Biopharma
(650) 823-7681
ewhite@sutrobio.com
Media Contact
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com
FAQ
What investor conferences will Sutro Biopharma (STRO) attend in May 2025?
How can investors access Sutro Biopharma's (STRO) conference presentations?
What is Sutro Biopharma's (STRO) main business focus?
Where will the BofA Securities 2025 Health Care Conference featuring Sutro Biopharma take place?
